CAS: 1316755-16-4 - (3S)-2-(2,2-Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylic acid
Formula:C32H29NO5
InChI:InChI=1S/C32H29NO5/c1-37-28-18-17-25-20-33(31(34)29(23-13-7-3-8-14-23)24-15-9-4-10-16-24)27(32(35)36)19-26(25)30(28)38-21-22-11-5-2-6-12-22/h2-18,27,29H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
InChI key:InChIKey=GHBCIXGRCZIPNQ-MHZLTWQESA-N
SMILES:O=C(O)C1N(C(=O)C(C=2C=CC=CC2)C=3C=CC=CC3)CC4=CC=C(OC)C(OCC=5C=CC=CC5)=C4C1
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | PD-126055 free acid REF: IN-DA009CMECAS: 1316755-16-4 | 97% | To inquire | Tue 10 Dec 24 |
 | Olodanrigan REF: TM-T4431CAS: 1316755-16-4 | 94.13% | 47.00 €~424.00 € | Tue 17 Dec 24 |
 | Olodanrigan REF: 3D-RCC75516CAS: 1316755-16-4 | Min. 95% | - - - | Discontinued product |
PD-126055 free acid
CAS:1316755-16-4
Formula:
C32H29NO5
Purity:
97%
Color and Shape:
Solid
Molecular weight:
507.5764
Ref: IN-DA009CME
| 1g | To inquire | ||
| 5mg | 94.00 € | ||
| 10mg | 127.00 € | ||
| 25mg | 180.00 € | ||
| 50mg | 303.00 € | ||
| 100mg | 563.00 € | ||
| 250mg | 597.00 € |
Estimated delivery in United States, on Tuesday 10 Dec 2024
Olodanrigan
CAS:1316755-16-4
Olodanrigan (EMA401), a highly selective AT2R antagonist, inhibition of augmented AngII/AT2R induced p38 and p42/p44 …
Formula:
C32H29NO5
Purity:
94.13%
Color and Shape:
Solid
Molecular weight:
507.58
Ref: TM-T4431
| 5mg | 47.00 € | ||
| 10mg | 72.00 € | ||
| 25mg | 112.00 € | ||
| 50mg | 198.00 € | ||
| 100mg | 294.00 € | ||
| 200mg | 424.00 € | ||
| 1mL*10mM (DMSO) | 49.00 € |
Estimated delivery in United States, on Tuesday 17 Dec 2024
Olodanrigan
CAS:1316755-16-4
Olodandrin is a molecule that is used in the treatment of skin cancer. It is …
Formula:
C32H29NO5
Purity:
Min. 95%
Molecular weight:
507.58 g/mol
Ref: 3D-RCC75516
| 5mg | Discontinued | Request information | |
| 10mg | Discontinued | Request information | |
| 25mg | Discontinued | Request information | |
| 50mg | Discontinued | Request information | |
| 100mg | Discontinued | Request information |
